<DOC>
	<DOCNO>NCT02042196</DOCNO>
	<brief_summary>As woman get old go menopause , level female reproductive hormone estradiol decrease low level . Also age , function artery decline . Over time vascular dysfunction lead health problem high blood pressure heart disease . This study do help determine cause artery become unhealthy postmenopausal woman , low level female reproductive hormone estradiol . In study test whether low level tetrahydrobiopterin ( BH4 ) , natural substance body cause artery expand , explain artery become unhealthy woman low level estradiol . To answer question , study vascular function change medication cause short-term increase BH4 level estradiol lower medication , compare estradiol normal . We also determine whether administration antioxidant vitamin C , along medication increase BH4 level , normalize vascular health perimenopausal postmenopausal woman , woman estradiol level lower .</brief_summary>
	<brief_title>Sex Hormones Atherosclerosis Prevention Perimenopausal Women</brief_title>
	<detailed_description>Endothelial dysfunction , feature reduce vascular endothelial-dependent dilation ( EDD ) , significant predictor cardiovascular ( CV ) event . Reduced EDD characterized loss nitric oxide ( NO ) production . EDD decline age woman slow rate compare men rapidly decline menopause quickly catch men , suggest beneficial effect estrogen ( E2 ) . Our research investigate mechanism underlie endothelial protection E2 include hormonal fluctuation peri-to early postmenopausal year contribute endothelial dysfunction , hormonal change might interact age . Using well describe experimental model ( systemic infusion ascorbic acid ; AA ) acutely reduce reactive oxygen specie ( ROS ) , preliminary finding implicate oxidative stress underlie mechanism explain impaired EDD menopausal transition . Specifically find improved EDD response AA late peri- postmenopausal woman pre- early perimenopausal woman . These data indicate E2 may protect vasculature free radical injury pre- early perimenopausal year . In support concept , demonstrate AA reverse decrease EDD occur set short-term E2 deficiency ( 3-days gonadotropin release hormone antagonist ; GnRHant ) pre-and early perimenopausal woman . Tetrahydrobiopterin ( BH4 ) critical co-factor production NO endothelial nitric oxide synthase ( eNOS ) , face deficient level , uncouple eNOS result production ROS instead NO . Whether increase ROS impair EDD occur peri- early postmenopausal period associate reduce vascular BH4 present unknown . However , find AA could improve reduce EDD find early perimenopausal woman restore EDD peri-and postmenopausal woman premenopausal level , indicate source ROS cause low NO involved impair EDD across stage menopause transition age woman . In vitro study demonstrate co-administration BH4 AA completely prevent eNOS uncouple decreased NO production endothelial cell treat peroxynitrite ( ONOO- ) donor , compare administer either one alone . The global aim renewal follow-up previous finding determine role BH4 mediator endothelial dysfunction [ across stage menopausal transition age woman . This global aim address 3 specific aim ( SA ) . Using cross-sectional design , SA1 measure EDD healthy pre- , peri- postmenopausal woman : 1 ) basal condition ; 2 ) follow acute increase BH4 . SA2 expand cross-sectional comparison via short-term ( 10 day ) ovarian suppression ( GnRhant ) pre-and early perimenopausal woman isolate age-independent effect E2 . SA3 examine whether co-administration BH4 AA fully restore youthful EDD peri-and postmenopausal woman . SA1 : To determine possible mechanistic involvement BH4 deficiency decline endothelial function peri-and early postmenopausal period potential relation oxidative stress . This assess compare brachial artery EDD plasma endothelial cell marker oxidative stress NO ( see method detail ) healthy pre- , peri-and postmenopausal woman : 1 ) basal condition ; 2 ) response acute oral BH4 ( v PL ) supplementation . Hypothesis1 ( H1 ) : ) EDD increase response BH4 early peri , late peri postmenopausal woman premenopausal woman . b ) The increase EDD response BH4 associate decrease plasma marker oxidative stress . c ) The reduce EDD peri- postmenopausal woman associate low endothelial cell markers NO higher oxidative Stress . SA2 : To determine whether decrease EDD response acute ovarian suppression pre- early perimenopausal woman relate reduced BH4 bioavailability elevate marker oxidative stress . This assess compare EDD plasma marker oxidative stress acute oral supplementation BH4 ( PL ) follow either acute ovarian suppression ( GnRHant+E2 ) without ( GnRHant+PL ) E2 add-back . Additionally , endothelial cell protein expression marker BH4 biosynthesis oxidative stress measure suppression/add-back paradigm . H2 : ) The expected decrease EDD increase plasma oxidative stress marker follow acute ovarian suppression mitigate group treat oral BH4 ( GnRHant+PL+BH4 ) ; little effect addition BH4 E2 add-back group . b ) Ovarian suppression alone reduce endothelial protein marker BH4 biosynthesis increase marker oxidative stress . These change observe follow ovarian suppression E2 add-back oral BH4 . These set experiment provide evidence oxidative stress-related decrease EDD response E2 suppression part , relate decrease BH4 bioavailability . SA3 : To determine whether co-administration BH4 AA completely restore EDD peri-and postmenopausal woman , early perimenopausal woman follow ovarian suppression . H3 : The co-administration BH4 AA restore EDD premenopausal level ) peri-and postmenopausal woman , b ) early perimenopausal follow acute ovarian suppression .</detailed_description>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Cetrorelix</mesh_term>
	<criteria>age criterion establish pre , peri postmenopausal woman , postmenopausal least 1 year beyond menopause rest blood pressure &lt; 140/90 mmHg 81 ; 2 ) plasma glucose concentration &lt; 110 mg/dl fast condition sedentary recreationally active ( &lt; 3 day vigorous aerobic exercise ) use OCs , HT , medication might influence cardiovascular function nonsmoker use vitamin supplement , NSAIDS willing stop use duration study take medication would interact cetrotide , E2 patch , KuvanÂ® confound interpretation result history active estrogendependent neoplasm , acute liver gallbladder disease , vaginal bleeding , venous thromboembolism , hypertriglyceridemia , CVD know allergy transdermal patch , GnRHant ( i.e. , hypersensitivity cetrorelix , extrinsic peptide hormone , mannitol , GnRH , benzyl alcohol vehicle injection cetrorelix ) , KUVAN history stomach ulcer bleed contraindication HRT , GnRHant , KUVAN ( i.e. , take Levodopa , medication inhibit folate metabolism include methotrexate ) pregnant currently breastfeed Other condition individual exclude study include : diabetes , active infection , history seizure disease affect nervous system , sepsis abnormal resting ECG</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>endothelial function</keyword>
	<keyword>woman</keyword>
	<keyword>estrogen deficiency</keyword>
	<keyword>sex hormone</keyword>
	<keyword>adiposity</keyword>
	<keyword>oxidative stress</keyword>
	<keyword>antioxidant</keyword>
</DOC>